# XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation

> **NCT06936527** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **NovaOnco Therapeutics Co., Ltd.** · enrollment: 102 (estimated)

## Conditions studied

- Colorectal Cancer
- Metastatic Colorectal Cancer With RAS Mutation

## Interventions

- **BIOLOGICAL:** Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI
- **BIOLOGICAL:** Drug: XS-03
- **BIOLOGICAL:** Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI

## Key facts

- **NCT ID:** NCT06936527
- **Lead sponsor:** NovaOnco Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-05-23
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-07-30
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06936527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06936527, "XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06936527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*